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T-wo different human malignant squamous cell lines 
(SCL-1 and SW-1271) and normal human foreskin fi-
broblasts were treated with recombinant human alpha, 
beta and gamma interferons. HLA-DR expression was 
indu:::ed in a concentration-dependent fashion only on 
the SCL-1 cells treated with recombinant human gamma 
interferon (r-IFN-'Y) (102-103 U/ml). No HLA-DR 
expression was observed with alpha or beta interferon 
on either malignant squamous cell line, nor with gamma 
interferon on SW-1271 cells. All three interferons re-
duced the number of malignant cells growing in culture 
but had no effect on the fibroblasts. There was a concen-
tration-dependent growth-inhibitory response of the 
malignant cells by the interferons (dose range 1-103 u; 
ml; 7.1 x 10-12 M to 7.1 x 10-9 M). The SCL-1 cells were 
102 more sensitive (based on weight) to the antiprolifer-
ative effects of gamma interferon than alpha or beta 
interferon. A brief (30-min) exposure of the SCL-1 cells 
to r-IFN-'Y (102 and 103 U/ml) produced approximately 
the same inhibition of cell growth as continuous expo-
sure over a 2-week period. The SW-1271 cells were 
equally sensitive to alpha, beta, and gamma interferons. 
HoW'ever, the maximal inhibitory effect on SW-1271 
cells was less than that observed for the SCL-1 cells. 
Combining beta and gamma interferon resulted in cy-
totoxicity with SCL-1 cells and additive cytostatic effect 
on the SW-1271 cells. These additional malignant cell 
lines with their different sensitivities to alpha, beta, and 
gamma interferons may prove useful in studying the 
mechanisms of action of various interferons. 
Interferons are currently classified into 2 different groups, 
t ypes I and II [1] . Type I interferons inclu~e alpha-interferon 
(IFN -a:) derived from leukocytes and beta-mterferon (IFN-m 
derived from fibrob lasts [2] . Gamma-interferon (IFN-')') is clas-
sified as Type II (or immune) and is a lymphokine derived from 
T lymphocytes [3] . IFN-a and IFN-,B are related (approxi-
mately 30% homology at the amino acid level), whereas IFN-'Y 
shows on ly s light homology with IFN-a or IFN-,B [4] . Interfer-
ons were originally described as antiviral agents [5]; however, 
interferons also have other properties. The first reported non-
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antiviral activity was the inhibiting effect on cell multiplication 
[6]. In addition, interferons inhibit tumor growth in animal 
models [7] and can affect a wide range of immunomodulatory 
functions [8]. Previous investigators have reported that highly 
purified (but not recombinant) IFN-'Y is more potent than IFN-
a as an antiproliferative agent (8- 10]. More recent data, how-
ever, utilizing pure recombinant interferon, reveal that IFN-'Y 
is less potent as an antiproli ferative agent than IFN -a in human 
melanoma cells [11]. Furthermore, combination of Type I and 
Type II interferons have resulted in potentiation of the anti-
cellular activity on murine and human melanomas and on a 
murine epidermal cell line [11- 13]. 
Since we have previously investigated the ability of human 
recombinant interferon to induce HLA-DR expression and 
inhibit proliferation of melanoma cells and keratinocytes, this 
work extends our observations to include malignant squamous 
carcinoma cells derived from t he skin and lung [14-16] . With 
the availability of recombinant, biosynthetically pure interfer-
ons and the increasing clinical and oncologic applications of 
t hese agents in dermatology [17], we sought to determine the 
relative immunomodulating and antiproliferative efficacies 
based on weight (molarity) of recombinant human alpha (r-
IFN-a), beta (r-IFN-,8), and gamma (r-IFN-')') interferons on 2 
human malignant squamous cell lines and foreskin fibroblas t s. 
MATERIALS AND METHODS 
Cell Culture Conditions 
The SCL-1 cells, derived from a poorly ctifferentiated human cuta-
neous squamous cell carcinoma, were obtained from Dr. N. Fusenig 
[18]. A second malignant human squamous cell line, SW-1271 , was 
derived from a pulmonary squamous cell carcinoma [19] and was the 
generous gift of Dr. R. Reisfeld. The human fibroblasts (passage #12) 
utilized were derived in our laboratory from a piece of normal human 
foreskin using an explant method [20] . 
All cells were grown on 3.5-cm plastic Petri rushes and grown in 
Dulbecco's modified Eagle's mectium supplemented with 10% heat-
inactivated fetal calf serum (FCS) and 50 l'g/ ml gentamicin. The cells 
were seeded at a density of 1. 7 X 106 cells per ctish and interferon was 
added 2 days after seecting. All time points incticated for cell counts 
refer to this time of addition of interferon as day 0. 
Interferon. Preparations 
Purified to homogeneity, human r-IFN-a A (M, = 19,500) was 
generously supplied by Dr. P. H. Johnson (Genentech, San Francisco, 
California). The specific activity was 1.56 x 108 reference units/ mg 
protein (U/ mg) as determined by virus inhibition plaque assay. The 
final protein concentration of 19.8 x 103 U/ ml (in each Petri ctish 
which contained 2 ml of mectia) was 0.128 l'g/ ml which equals 6.6 x 
10-9 M. 
Purified to homogeneity, human r-IFN-1'1 (Cetus Corp., Palo Alto, 
California) had a specific activity of 14.8 x 107 U/ mg as determined by 
virus inhibit ion plaque assay. Since the M, of r-IFN -ti is 16,500, the 
final protein concentration of 21.8 x 103 U/ ml was 0.147 mg/ ml which 
equals 8.9 x 10- 9 M. 
Purified to homogeneity, human r-IFN--y (M, = 17,000) was gener-
ously supplied by Dr. G. Burton (Genentech) . The specific activity was 
8.2 X 106 U/ mg as determined by virus inhibition plaque assay. The 
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final protein concentration of 1 X 103 U/ml was 0.122 J.Lg/ml which 
equals 7. 1 x 10-9 M. 
Fluorescein Labeling and FAGS Analysis 
The cultured cells were washed to remove nonattached cells and the 
monolayer was trypsini >.ed for 10 min using 0.3% trypsin plus 0.1% 
EDTA and washed with Dulbecco's phosphate-buffered saline (DPBS) 
conta ining Ca2+ and MgH AliquotB of 5 X 106- 106 viable cells were 
indirectly stained for 20 min on ice with 1 l'g of ant i-HLA-DR mono-
clonal antibody L243 (lgG2.) or Leu-2b (lgG •• ) (Becton Dickinson 
Monoclonal Center, Inc., Mountain View, California) diluted in heat-
inactivated FCS containing 0.1 % sodium azide. Nonspecific and Fe 
receptor mediated background staining was determined by substituting 
control isotype (Leu-2b) for the first step. The cells were then washed 
twice with DPBS and stained for 20 min with 1 l'g fluorescein isothio-
cyanate (FITC)-conjugated goat antimouse IgG monoclonal antibody 
(Becton-Dickinson). The labeled cells were diluted with DPBS and 
centrifuged t hrough a layer of heat- inactivated FCS. The cells were 
then washed with DPBS and fixed with 1% paraformaldehyde in 
phosphate-buffered saline (PBS). The fluorescence per ce ll was deter-
mined wit h a fluorescence-activated cell sorter (FACS III; Becton-
Dickinson). and a histogram showing the number of stained cells 
aga inst the intensity of fluorescence was recorded. 
Determination of Cell Number 
Cell counts were performed with a hemocytometer using an Olympus 
inverted microscope. The monolayer cultures were initially rinsed with 
PBS and incubated with 1 ml of 0.3 % trypsin, 0.1 % EDTA (10 min, 
Cl7"C) per plate and rinsed with 1 ml of complete medium. An aliquot 
(0.1 ml) was mixed with an equal volume of trypan blue (0.08%) to 
determine viabili ty. Each cell count determination represents the av-
erage of the means obtained on duplicate dishes (±SEM) . The attached 
cells were greater than 90% viable in all experiments. Statistical 
significance was determined by the Student t-test. 
RESULTS 
T he FACS profile of SCL-1 cells t reated with r-IFN--y (102 
U/ml, 0 .71 nM ; day 3) reveals s ignificant HLA-DR expressio n 
compared to control, untreated cultures (Fig 1). Table I sum -
marizes the percentage of cells stained and mean flu orescence 
for SCL-1 cells treated with various interferon preparations . 
No induction of HLA-DR expression on SCL-1 resulted after 
r -IFN -a or r -IFN-tl . There was a concen tration -depende nt 
increase in HLA-DR exp ression by r-IFN-'Y and no further 
increase by combining r-IFN-tl plus r-IFN--y. None of t he 
in terfero ns induced HLA-DR on SW -1271 cells or fibroblasts . 
Fig 2 summarizes t he antiproliferative effect of interferon on 
SCL-1 cells. Con t inuous exposure to r-IFN-'Y (1 - lO:l U/ml) 
resulted in a co ncentratio n -dependent inhibition of prolife ra-
tion. At lO:l U/ml, r -IFN --y produced a total cytostatic effect, 
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FIG l. FACS profile of HLA-DR expression of SCL-1 cells treated 
with r-lFN-1' (102 U/ml) on day a compared to untreated controls. 
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TABLE I. HLA -DR expression of SCL-1" cells on day 3 
Percent cells stained' Mean' 






r-IFN-a (19.8 X 103 U/ml, 6.6 nM) 
r-IFN-13 (2.18 X 103 U/ml, 8.9 nM) 
r-!FN-1' (102 U/ml, 0.71 nM) 
r -IFN -1' (103 U/ml, 7.1 nM) 




"There was no detectable HLA-DR expression on SW-1271 or 
fibroblasts under similar conditions. 
• Background and nonspecific fluorescence have been subtracted. 
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FIG 2. SCL-1 cells were incubated with various concentrations of r-
!FN--y (103 U/ml, 7.1 nM ), both continuously and as a 30-min pulse. In 
both cases, r-IFN- -y inhibited cell growth in a concentration-dependent 
manner. To control for residual r-IFN--y remaining in t he cultures 
pulsed for 30 min with 1000 U/ml r-IFN --y, the second wash medium 
from these cultures was used as the medium for a control culture. r -
IFN-13 (2.18 X 103 U/ml, 8.9 nM) also inhibited cell growth. r-IFN-tl 
plus r-!FN --y appeared to be cytotoxic. 
TABLE II. Differential effect of r-IFN-c., r-IFN-13, and r-1 FN--y on the 
growth of SCL-1 celL~ (cell number, % of control) 
r- IFN-" 
Day 1.98 X 10
2 U/ml 1.98 X 10" U/ml 1.98 X 10' U/ ml 
6.6 X J0- 11 M 6.6 X 10- 10 M 6.6 X J0- 9 M 
3 100 ± 4 85 ± 4 77 ± 4 
5 89 ± 3 70 ± 3 55± 3 
8 84 ± 3 50± 4 42 ± 4 
r-IFN-{:J 
Day 2. 18 X 10
2 U/ml 2.18 X 103 U/ml 2.18 x 10' U/ ml 
8.9 X 10-11 M 8.9 X 10- 10 M 8.9 X 10-9 M 
3 100 ± 4 92 ± 4 72 ± 4 
5 78 ± 4 60 ± 3 44 ± 4 
8 72 ± 4 54 ± 3 38 ± 4 
r-IFN--y 
Day I U/ml 10 U/ml 100 U/ml 1000 U/ ml 7. 1 X 10- 12 M 7.1 X 10- 11 M 7. 1 X 10- 10 M 7.1 X 10- 9 M 
3 68 ± 3 62 ± 3 53 ± 4 44 ± 4 
5 75 ± 3 58± 3 38 ± 3 26 ± 3 
8 75 ± 4 61 ± 4 32 ± 3 14 ± 4 
i.e., no change in number o f attached viable cells. Whereas 
eit her r -IFN -tl o r r -IFN --y produced a cytostatic effect a lone, 
combining r-IFN -tl with r -IFN--y produced a cytotoxic effect 
with reduction in cell numbe r below the initial level. A brief 
exposure for 30 min of t he SCL-1 cells to r -IFN--y at 102 U/ml 
(0.71 X 10- 9 M) a nd 10'' U/ml (7.1 X 10- 9 M) resulted in 
significant growth inhibition despite repeated washes and me-
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dia changes. To exclude t he possibility that the growth-inhibi-
tory effect seen in a pulsed cultu re was due to residual r-IFN-
'Y we assayed the final wash after exposure to 10" U/ ml (7.1 X 10-9 M). This wash media revealed only slight residua l inhibi-
tory activity , but clearly not suffic ient to explain the signifi-
cantly greater continued prolonged inhibition seen in the cul -
ture pulsed with 103 U/ml of r-IFN- ')'. 
Table II compares the differential effect of r-IFN-a , r-IFN-
{3, and r-IFN -')' on the SCL-1 ce lls. On day 5, r-IFN-')' at 1 Uj 
ml (7.1 x 10- 1> M) resulted m 75 ± 3% ofcontrolm cell number 
which is approximately 102 more potent than r-IFN-a (70% ± 
3.0, 1.98 X 103 U/m l, 0.66 nM ; p < .05). 
Table III compares the differential effects ofr-IFN-a, r-IFN-
{3, and r-IFN -')' on SW-1271 ce lls. Unlike the SCL-1 cells, there 
is an approximately equal reduction in cell number by all 3 
interferons. However, the maximal inhibition by r-IFN- ')' was 
less on the S W -1271 cells compared to the SCL-1 cells. By 
combining r-IFN -{3 and r-IFN-')', there was an additive cyto-
static effect. We have also studied the effect of r-IFN -a, r-IFN-
{3, and r-IFN -1' on normal foreskin fibro~last cultures (passage 
#12) but observed no effect on cell prohferatwn or HLA-DR 
expression despite an antiviral effect (VSV) at the highest 
concentrations (data, not shown) . 
DISCUSSION 
r-IFN-')' induced significant HLA-DR expression on the 
SCL-1 but not on SW -1271 cells. While r-IFN-a and r-IFN-{3 
also inhibited the proliferation of SW-1271 cells, HLA-DR was 
not induced by these interferons. The differential effect be-
tween HLA-DR expression and antiproliferation has been pre-
viously observed on cultured human melanoma cell lines [14] . 
r-IFN-')' was 102 times more potent than r -IFNs-a and -{3 on 
t he SCL-1 cells as an antiproliferative agent and was approxi-
mately equally efficacious on the SW -1271 cells (Tables II, III). 
Our results compare favorably with those previously reported 
using nonrecombinant interferon preparations (8-10]. The in-
creased efficacy (based on weight) of r-IFN -')' over r- IFN -a and 
-{3 on the SCL-1 cells contrasts with recent work in which r-
IFN -a was superior to r- IFN -')' on human melanoma cells 
(Hs294T) (11). Clearly, additional studies utilizi~g ~variety of 
malignant cells are required before any generahzatwn can be 
made regarding the relative antiproliferative properties of the 
different types of recombinant interferons. The combinations 
of Types I and II interferon produced two different effects on 
t he SCL-1 and SW-1271 cells. 
On the SCL-1 cells, r-IFN-{3 plus r-IFN-')' produced a cyto-
toxic effect whereas on t he SW -1271 cells, there was an additive 
cytostatic effect. Previous investigators have observed a syn-
ergistic antiproliferative effect with combination of Types I 
and II interferon on human melanoma cells and murine malig-
nant epithelial cells (11- 13]. Since cultured human keratino-
cytes produce IFN-{3 [21 ) and t here is a conspicuous lympho-
cytic inflammatory infiltrate (potential source of IFN-a and 
-')') in cutaneous basal cell and squamous cell carc inomas (22], 
further studies investigating t he combined effects of interferons 
with respect to cytostatic/cytotoxic and immunomodulatory 
effects (HLA-DR expression) may reveal new insights into t he 
role of t he immune system in controlling benign and malignant 
keratinocyte growth [23]. 
To investigate the reversibili ty of inhibition of cell prolifer-
ation, we studied the effect of r-IFN- ')' after a brief (30-min) 
exposure. At both 102 U/ ml and 103 U/ ml, r-IFN-'Y resulted in 
an inhibition SCL-1 cell proliferation which was not readily 
reversible (Fig 2). This result is similar to the previous report 
in which 1-h incubation was identical to continuous exposure 
in reducing cell proliferation by interferon (24). From an analy-
sis of the second and final wash in which only slight residual 
inhibitory activity could be observed, it appears that the con-
tinued presence of r-IFN -')' in the medium is not necessary for 
the antiproliferative effect. Whethe~ t hese cells release a con-
tinuous low level of initially bound IFN-I' from t he cells into 
the medium, which has been previously documented in mouse 
L cells [25], or whether the IFN-')' induces production of a 
secondary message molecule by the pulsed cells which also has 
been reported with mouse L cells (26], is presently unknown. 
The lack of antiproliferative response of human foreskin 
fibroblast cultures to either r-IFN-a, r-IFN-{3, or r-IFN-')' dif-
fers from previous reports utilizing various cultured fibroblasts 
[9,24,27]. One of these reports observed that both Types I and 
II interferon were antiproliferative agents on human fibroblasts 
(FS-4) as determined by reduction in [3H]thymidine incorpo-
ration (9). While our foreskin fibroblast cultures may be differ-
ent from the fibroblast cell line used in that report, an addi-
tional complicating factor, besides our use of recombinant 
rather than purified natural IFN, is the interpretation of (3H] 
thymidine incorporation as a measure of cell proliferation. We 
have elected to perform cell counts rather than [3H]thymidine 
incorporation since it has been reported that IFN-a directly 
inhibits [3H)thymidine uptake prior to an inhibitory action on 
cell multiplication [28[ . Finally, the discrepancy between our 
results and those of others may be related to the fact that we 
have used very early passaged fibroblasts . A recent publication 
TABLE III. Differential effects of r-IFN-a, r-IFN-{3, and r-IFN--y on SW-1271 cells (cell number, % of control) 
r-IFN-a 
Day 
1.98 X 102 U/ ml 1.98 x 103 U/ml 1.98 x JO' U/m l 
6.6 X J0- 11 M 6.6 X JO- Io M 6.6 X 10_, M 
3 95 ± 4 96± 4 100 ± 4 
5 89 ± 4 90 ± 8 90 ± 8 
7 56± 3 85 ± 4 77 ± 4 
11 80 ± 4 72 ± 3 63 ± 3 
r-/FN-{J 
2.18 X 102 U/ ml 2.18 X 103 U/ ml 2.1 8 X 10' U/ ml r-IFN -{1 (8.9 X 10-• M) Day 8.9 X 10-11 M 8.9 X 10- 10 M 8.9 X w-• M plus 
r-IFN --y (7. 1 X w-• M) 
3 98 ± 4 91 ± 4 81 ± 4 62 ± 4 
5 85 ± 3 78 ± 4 65 ± 4 38 ± 5 
7 74 ± 6 65 ± 5 55± 6 32 ± 5 
r-1FN--y 
Day 
10 U/ ml 100 U/ ml 1000 U/ml 
7. 1 X 10-11 M 7.1 X JO-Io M 7.1 X 10-9 M 
3 91 ± 4 88 ± 4 78 ± 4 
5 86 ± 4 79 ± 4 75 ± 4 
7 82 ± 4 76 ± 4 72 ± 4 
11 72 ± 4 65 ± 4 60 ± 4 
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(29] ut ilizing a diploid fibroblast cell line has found t ha t the 
effect of IFN -!3 on DNA synt hesis depended o n t he number of 
passages (populat ion doubling levels ). IFN-!3 dec reased cells 
numbe r in both early- and late-passaged fibroblast cultures, 
but t he re was a loss of t he effect of inhibit ing DNA syn t hesis 
which was seen in early cult ures compa red t o t he later-passaged 
cells . Whether our fibroblasts will become sens itive t o the 
a nt iproliferative e ffect s of in terferon with con t inued senes -
cence is currently being investigated . The abili ty of the inte r-
ferons to confer a n antiviral state on t he fibroblasts without 
a ffecting proliferatio n or HLA-DR expression has been ob-
served on melanoma cell lines [14). 
Wit h t he adven t of recombinant biosynthetica lly pure inte r-
ferons, precise examinatio n of diffe rential biologic efficacies o f 
huma n types I and II interferon based on weight, receptor 
ligand-b inding a ffini ty a na lysis , a nd cell cycle -dependent 
growth inhibi t ion is now possible. The di fferen t ial sens itivity 
of t hese cell lines to t he interferon s uggests t hat t he re may be 
di fferences in t he t hera peut ic effi cacy of interfe rons against 
differe nt tumors (23]. 
The authors wish to thank Eva Pfendt for providing excellent 
technical assistance. 
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